(Sharecast News) - Drugmaker Astrazeneca said on Friday that it has expanded its weight‑management pipeline after striking a strategic collaboration with CSPC Pharmaceuticals to develop a series of next‑generation obesity and type‑2 diabetes therapies.
Under the deal, AstraZeneca will gain exclusive global rights outside China to CSPC's monthly injectable portfolio, including...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE